CALT(Delisted)
CalliditasยทNASDAQ
--
--(--)
CALT Profile
Calliditas Therapeutics Ab
A commercial stage biopharma company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications
--
02/20/2004
06/05/2020
NASDAQ Stock Exchange
217
12-31
Depository Receipts (Ordinary Shares)
Kungsbron 1, D5, SE-111 22, Stockholm, Sweden
--
Founded on February 20, 2004, Calliditas Therapeutics AB is a clinical-stage biopharmaceutical company dedicated to identifying, developing and commercializing new therapies for orphan indications, with an initial focus on kidney and liver diseases with unmet medical needs, the lead drug candidate, Nefecon, is a novel proprietary oral formulation of budesonide, an established, An effective topical immunosuppressant for the treatment of autoimmune kidney disease IgA nephropathy or IgAN, which is in high medical demand and there are no approved treatments. IgAN is a progressive chronic disease that over time leads to deterioration of kidney function in patients, many of whom are at risk of eventually developing end-stage renal disease or ESRD, requiring dialysis or kidney transplantation. Nefecon is currently the only disease-modifying drug candidate in IgAN development.
